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Abstract
Pancreatic endocrine tumors (PETs) arise sporadically
or are associated with multiple endocrine neoplasia
type 1 (MEN1) syndrome or von Hippel-Lindau syn-
drome. About 90% of patients with familial MEN1
display detectable MEN1 gene (menin) mutations. The
cyclin-dependent kinase inhibitor p27 (CDKN1B) is a
downstream target of menin and has been recently
shown to be responsible for the multiple endocrine
neoplasia–like syndrome in rats, where affected ani-
mals develop multiple tumors and hyperplasia in en-
docrine tissues, including the pancreatic islets of
Langerhans. A germline nonsense truncation mutation
of p27 has been recently described in a suspectedMEN1
family without MEN1 mutation, raising the possibility
that p27mutation could be responsible for MEN1pheno-
type. SomaticMEN1mutations occur at low frequency in
sporadic PETs; here, we subjected p27 to mutational
analysis in 27 sporadic PETs. As an additionalmenin tar-
get, analysis of the p18 (CDKN2C) gene was included. In
the p27 gene, one common polymorphism (V109G) and
one novel polymorphism (g/a) in the noncoding part of
exon2were identified.Threeknownpolymorphismswere
found in the p18 gene. These data suggest that p27 and
p18 are unlikely to present classic tumor-suppressor
genes in sporadic PETs.
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Introduction
Pancreatic endocrine tumors (PETs) constitute benign and
malignant lesions that are classified according to symp-
toms of hormonal excess or are considered nonfunction-
ing. PETs arise sporadically from or in association with
multiple endocrine neoplasia type 1 (MEN1) syndrome and
von Hippel-Lindau syndrome. The prevalence of detected
germline mutations of the MEN1 gene on chromosome
11q13 in MEN1 families is about 90%, and affected individ-
uals classically suffer from tumors of the pituitary gland, para-
thyroid glands, and endocrine pancreas [1–5]. The MEN1
gene is less frequently mutated in sporadic PETs [6–8].
The gene responsible for the multiple endocrine neoplasia–
like syndrome in rats has been recently identified as the cyclin-
dependent kinase inhibitor p27. The affected animals devel-
oped endocrine pancreatic hyperplasia, parathyroid adenomas,
paragangliomas, bilateral pheochromocytomas, and multifocal
thyroid C-cell hyperplasia [9]. A germline nonsense truncation
mutation in p27 was detected in several members of a family
with a variant of the MEN1 syndrome, with tumors of the
parathyroid and pituitary glands, and without identifiable MEN1
mutation. Based on these findings, it was suggested that germ-
line mutations in p27 can predispose to the development of
multiple endocrine tumors in both rats and humans [9,10].
Experiments in mice also support a tumorigenic role of p27, as
well as of p18. Knockout of the p18 or the p27 gene in mice
caused widespread hyperplasia and organomegaly, as well as
tumor formation [11]. Double p18/p27 knockout mice developed
multiple tumors of endocrine organs, including pancreatic islet
hyperplasia [11]. Double p27/MEN1 knockout mouse models
have demonstrated that combined gene loss did not increase
pancreatic islet tumor development, whereas double p18/MEN1
knockout mice developed increased rate of tumors [12]. Menin,
the product of the MEN1 gene, has been shown to positively
regulate the transcription of the p27 and p18 genes in mouse
pancreatic islets [13,14]. We examined the p27 and p18 gene
mutational status in sporadic human PETs.
Materials and Methods
Patients and Tumor Samples
Twenty-seven patients were recruited and tissue specimens
were collected during clinical routine at the Uppsala University
Hospital, with informed consent and approval of the ethics
committee. Twenty-seven sporadic PETs were investigated,
including 10 benign insulinomas, 3 malignant insulinomas, 10
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malignant nonfunctioning tumors, 3 malignant glucagono-
mas, and 3 malignant gastrinomas. All investigated tumors
were primary tumors, except for tumor 5516, where lymph
node metastasis was observed (Table 1).
Polymerase Chain Reaction (PCR) and DNA
Sequencing Analysis
Tumor DNA was extracted from cryosections by standard
procedures after microdissection to avoid gross contamina-
tion by nontumor cells. Tumor cells were identified by immuno-
histologic staining using a synaptophysin rabbit polyclonal
antibody (A0010; DAKO A/S, Glostrup, Denmark). Coding
parts of the p27 and p18 genes were investigated using pre-
viously published primers [15]. PCR reactionswere conducted
on tumor DNA and blood DNA corresponding to tumor 3219
(new p27 gene polymorphism; see below), as described
previously [16], and dimethylsulfoxide was used when neces-
sary. Amplified PCR fragments were subjected to sequencing
on a 3130XL Genetic Analyzer using a BigDye Terminator
v3.1 Cycle Sequencing Ready Reaction Kit (Applied Biosys-
tems, Foster City, CA). Three known polymorphisms in the
CDKN2C/p18 gene were detected (Table 1): contig positions
21411375 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.
cgi?rs=3176471), 21411696 (http://www.ncbi.nlm.nih.gov/
SNP/snp_ref.cgi?rs=1043141), and 21412012 (http://www.
ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=12855) in contig
NT_032977. The common V109G polymorphism in the p27
(CDKN1B) gene was detected at the expected frequency
(5630073 in contig NT_009714; http://www.ncbi.nlm.nih.gov/
SNP/snp_ref.cgi?rs=2066827), as well as an unknown poly-
morphism in a noncoding part of exon 2 [5630867 (g/a) in
contig NT_009714].
Results and Discussion
Direct sequencing of the p27 and p18 genes was conducted
on 27 sporadic PETs. A previously unpublished polymorphism
was detected with a g/a nucleotide change at 13 bp after the
stop codon in the p27 gene (5630867 in contig NT_009714).
In addition, one (5630073 in contig NT_009714) and three
(21412012, 21411696, and 21411375 in contig NT_032977)
known polymorphisms were found in p27 and p18, respec-
tively (Table 1; see also Materials and Methods section). All
other sequences corresponded to GenBank. These findings
do not support a role for p27 and p18 as classic tumor-
suppressor genes in sporadic PETs.
In addition, a recent report found no evidence of the in-
volvement of p27 in 16 index cases of the MEN1 variant with
tumors of both parathyroid and pituitary glands and no
identified MEN1 mutation [17].
Whether p27 presents a crucial target in other endocrine
malignancies remains to be determined.
Table 1. Characterization of PETs Analyzed in This Study.
Tumor Number Tumor Syndrome Signs of Malignancy Follow-up (Years) p18 Polymorphism p27 Polymorphism
21412012 21411696 21411375 5630073 5630867
3945 Insulinoma None FD (14) ct ct aa gt gg
4642 Insulinoma None FD (13) ct ct aa tt gg
4741 Insulinoma None FD (13) cc cc aa tt gg
5735 Insulinoma None FD (12) cc cc aa tt gg
6832 Insulinoma None FD (8) ct ct aa gt gg
7436 Insulinoma None FD (6) cc cc aa tt gg
7602 Insulinoma None FD (6) cc cc aa tt gg
7701 Insulinoma None DO (4) ct ct aa gg gg
8113 Insulinoma None FD (4) ct ct aa gt gg
8341 Insulinoma None FD (3) cc cc aa gt gg
117 Insulinoma Lymph node metastases AWD (22) cc cc aa tt gg
8495 Insulinoma Lymph node metastases* AWD (3) cc cc at gt gg
8734 Insulinoma Infiltrative growth NR (2) ct ct aa gt gg
7495 Gastrinoma Liver metastases AWD (6) cc cc aa tt gg
2576 Glucagonoma Liver metastases AWD (17) cc cc aa tt gg
5516 Glucagonoma Lymph node metastasesy DRD (7) cc cc aa tt gg
8640 Glucagonoma Infiltrative growth NR (3) cc cc aa gt gg
2663 Nonfunctioning tumor Lymph node metastasesz DRD (10) cc cc aa tt gg
3219 Nonfunctioning tumor Liver metastases DRD (7) cc cc aa tt ag
5287 Nonfunctioning tumor Lymph node metastases§ AWD (12) cc cc aa gt gg
5620 Nonfunctioning tumor Liver metastases DRD (7) cc cc aa gt gg
6114 Nonfunctioning tumor Infiltrative growthb AWD (11) cc cc aa gt gg
7482 Nonfunctioning tumor Liver metastases DRD (1) cc cc aa gg gg
7536 Nonfunctioning tumor Lymph node metastases NR (6) cc cc aa gt gg
8227 Nonfunctioning tumor Liver metastases AWD (4) ct ct aa tt gg
8357 Nonfunctioning tumor Liver metastases AWD (3) cc cc aa gg gg
8970 Nonfunctioning tumor Liver metastases NR (2) cc cc aa tt gg
FD, free of disease; DO, death due to other causes; AWD, alive with disease; NR, no signs of recurrence; DRD, disease-related death.
*Liver metastases detected after 2 years.
yLiver metastases detected after 6 years.
zLiver metastases detected after 7 years.
§Liver metastases detected after 8 years.
bLiver metastases detected after 7 years.
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